Form 4: Camp4 Therapeutics CEO Acquires Stock Options
SEC Form 4 Filing
Josh Mandel-Brehm, CEO of Camp4 Therapeutics, reports the acquisition of stock options.
Summary
- Josh Mandel-Brehm, the CEO of Camp4 Therapeutics Corp, filed a Form 4 on April 3, 2025.
- The form reports a transaction that occurred on April 1, 2025, where Mandel-Brehm acquired stock options.
- He acquired options to buy 160,000 shares of common stock at an exercise price of $3.86.
- The options vest in equal monthly installments over four years, starting from the grant date.
- Following the transaction, Mandel-Brehm directly owns options for 160,000 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing related to executive compensation.
Positives
- The acquisition of stock options by the CEO could align his interests with those of the shareholders, incentivizing him to improve the company's performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- The acquisition of stock options by the CEO could potentially align his interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of stock option grant to Josh Mandel-Brehm. |
| 04/03/2025 | Date of Form 4 filing. |
| 03/31/2035 | Expiration date of the stock options. |
Keywords
Form 4, Stock Options, Camp4 Therapeutics, CEO, Mandel-Brehm, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.